Valneva SE
PAR:VLA
Valneva SE
Other
Valneva SE
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valneva SE
PAR:VLA
|
Other
-€19m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other
-€7.9m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-58%
|
|
|
Inventiva SA
PAR:IVA
|
Other
€129m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other
-$345k
|
CAGR 3-Years
8%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Other
-€12.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sensorion SA
PAR:ALSEN
|
Other
-€4.1m
|
CAGR 3-Years
-125%
|
CAGR 5-Years
-104%
|
CAGR 10-Years
N/A
|
|
Valneva SE
Glance View
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
See Also
What is Valneva SE's Other?
Other
-19m
EUR
Based on the financial report for Sep 30, 2025, Valneva SE's Other amounts to -19m EUR.
What is Valneva SE's Other growth rate?
Other CAGR 1Y
-1%
Over the last year, the Other growth was -1%.
